Protalix BioTherapeutics, Inc. (PLX)
USD 3.0
(0.0%)
USD 3.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 84.43 Million USD | 51.35% |
| 2022 | 55.78 Million USD | -24.27% |
| 2021 | 73.66 Million USD | 8.44% |
| 2020 | 67.93 Million USD | 49.66% |
| 2019 | 45.39 Million USD | -25.75% |
| 2018 | 61.13 Million USD | -15.35% |
| 2017 | 72.21 Million USD | -12.2% |
| 2016 | 82.24 Million USD | -15.43% |
| 2015 | 97.25 Million USD | 23.94% |
| 2014 | 78.47 Million USD | -30.76% |
| 2013 | 113.33 Million USD | 43.96% |
| 2012 | 78.72 Million USD | 51.97% |
| 2011 | 51.8 Million USD | -19.97% |
| 2010 | 64.72 Million USD | -34.4% |
| 2009 | 98.67 Million USD | 94.19% |
| 2008 | 50.81 Million USD | -25.43% |
| 2007 | 68.13 Million USD | 152.47% |
| 2006 | 26.98 Million USD | 2633.35% |
| 2005 | 987.36 Thousand USD | 74.5% |
| 2004 | 565.83 Thousand USD | -22.94% |
| 2003 | 734.25 Thousand USD | -16.11% |
| 2002 | 875.22 Thousand USD | -14.46% |
| 2001 | 1.02 Million USD | -46.27% |
| 2000 | 1.9 Million USD | -7.01% |
| 1999 | 2.04 Million USD | -57.09% |
| 1998 | 4.77 Million USD | -36.08% |
| 1997 | 7.46 Million USD | 1.73% |
| 1996 | 7.33 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 89.82 Million USD | 6.38% |
| 2024 Q2 | 91.54 Million USD | 1.91% |
| 2023 Q4 | 84.43 Million USD | -3.58% |
| 2023 FY | 84.43 Million USD | 51.35% |
| 2023 Q1 | 66.55 Million USD | 19.31% |
| 2023 Q2 | 88.41 Million USD | 32.84% |
| 2023 Q3 | 87.56 Million USD | -0.96% |
| 2022 Q4 | 55.78 Million USD | -1.63% |
| 2022 Q2 | 60.64 Million USD | -11.33% |
| 2022 Q3 | 56.7 Million USD | -6.48% |
| 2022 Q1 | 68.39 Million USD | -7.16% |
| 2022 FY | 55.78 Million USD | -24.27% |
| 2021 Q3 | 83.48 Million USD | -22.85% |
| 2021 Q1 | 102.79 Million USD | 51.31% |
| 2021 FY | 73.66 Million USD | 8.44% |
| 2021 Q4 | 73.66 Million USD | -11.76% |
| 2021 Q2 | 108.2 Million USD | 5.27% |
| 2020 Q4 | 67.93 Million USD | -6.05% |
| 2020 FY | 67.93 Million USD | 49.66% |
| 2020 Q1 | 82.87 Million USD | 82.58% |
| 2020 Q2 | 71.71 Million USD | -13.47% |
| 2020 Q3 | 72.31 Million USD | 0.84% |
| 2019 Q2 | 55.24 Million USD | -9.5% |
| 2019 Q3 | 53.72 Million USD | -2.74% |
| 2019 Q4 | 45.39 Million USD | -15.52% |
| 2019 Q1 | 61.04 Million USD | -0.14% |
| 2019 FY | 45.39 Million USD | -25.75% |
| 2018 Q3 | 67.19 Million USD | 29.92% |
| 2018 FY | 61.13 Million USD | -15.35% |
| 2018 Q4 | 61.13 Million USD | -9.03% |
| 2018 Q2 | 51.72 Million USD | -20.18% |
| 2018 Q1 | 64.79 Million USD | -10.27% |
| 2017 FY | 72.21 Million USD | -12.2% |
| 2017 Q3 | 61.05 Million USD | 3.49% |
| 2017 Q1 | 71.85 Million USD | -12.64% |
| 2017 Q4 | 72.21 Million USD | 18.27% |
| 2017 Q2 | 59 Million USD | -17.89% |
| 2016 FY | 82.24 Million USD | -15.43% |
| 2016 Q1 | 87.31 Million USD | -10.22% |
| 2016 Q2 | 78.86 Million USD | -9.67% |
| 2016 Q3 | 70.47 Million USD | -10.64% |
| 2016 Q4 | 82.24 Million USD | 16.71% |
| 2015 Q4 | 97.25 Million USD | 63.47% |
| 2015 Q3 | 59.49 Million USD | -9.8% |
| 2015 FY | 97.25 Million USD | 23.94% |
| 2015 Q1 | 72.04 Million USD | -8.18% |
| 2015 Q2 | 65.95 Million USD | -8.46% |
| 2014 FY | 78.47 Million USD | -30.76% |
| 2014 Q1 | 103.41 Million USD | -8.75% |
| 2014 Q4 | 78.47 Million USD | -7.46% |
| 2014 Q3 | 84.79 Million USD | -12.27% |
| 2014 Q2 | 96.65 Million USD | -6.54% |
| 2013 Q4 | 113.33 Million USD | -6.46% |
| 2013 Q3 | 121.15 Million USD | 94.45% |
| 2013 Q1 | 69.94 Million USD | -11.16% |
| 2013 Q2 | 62.3 Million USD | -10.92% |
| 2013 FY | 113.33 Million USD | 43.96% |
| 2012 Q4 | 78.72 Million USD | 1.74% |
| 2012 FY | 78.72 Million USD | 51.97% |
| 2012 Q3 | 77.37 Million USD | -8.22% |
| 2012 Q2 | 84.3 Million USD | 23.14% |
| 2012 Q1 | 68.46 Million USD | 32.16% |
| 2011 Q4 | 51.8 Million USD | -14.84% |
| 2011 FY | 51.8 Million USD | -19.97% |
| 2011 Q1 | 80.92 Million USD | 25.02% |
| 2011 Q2 | 71.88 Million USD | -11.16% |
| 2011 Q3 | 60.82 Million USD | -15.38% |
| 2010 Q2 | 74.23 Million USD | -16.07% |
| 2010 Q3 | 75.14 Million USD | 1.24% |
| 2010 FY | 64.72 Million USD | -34.4% |
| 2010 Q4 | 64.72 Million USD | -13.86% |
| 2010 Q1 | 88.44 Million USD | -10.37% |
| 2009 Q1 | 46.23 Million USD | -9.0% |
| 2009 Q4 | 98.67 Million USD | 158.84% |
| 2009 FY | 98.67 Million USD | 94.19% |
| 2009 Q3 | 38.12 Million USD | -9.64% |
| 2009 Q2 | 42.18 Million USD | -8.77% |
| 2008 Q2 | 61.82 Million USD | -6.09% |
| 2008 Q1 | 65.82 Million USD | -3.39% |
| 2008 FY | 50.81 Million USD | -25.43% |
| 2008 Q4 | 50.81 Million USD | -9.08% |
| 2008 Q3 | 55.88 Million USD | -9.6% |
| 2007 Q2 | 28.36 Million USD | -6.58% |
| 2007 Q4 | 68.13 Million USD | 155.1% |
| 2007 FY | 68.13 Million USD | 152.47% |
| 2007 Q1 | 30.35 Million USD | 12.49% |
| 2007 Q3 | 26.71 Million USD | -5.82% |
| 2006 Q4 | 26.98 Million USD | 3122.35% |
| 2006 Q3 | 837.52 Thousand USD | -11.43% |
| 2006 Q2 | 945.56 Thousand USD | -1.64% |
| 2006 Q1 | 961.28 Thousand USD | -2.64% |
| 2006 FY | 26.98 Million USD | 2633.35% |
| 2005 FY | 987.36 Thousand USD | 74.5% |
| 2005 Q4 | 987.36 Thousand USD | 96.58% |
| 2005 Q3 | 502.27 Thousand USD | -5.23% |
| 2005 Q2 | 530.01 Thousand USD | -4.4% |
| 2005 Q1 | 554.41 Thousand USD | -2.02% |
| 2004 FY | 565.83 Thousand USD | -22.94% |
| 2004 Q3 | 588.19 Thousand USD | -7.75% |
| 2004 Q2 | 637.63 Thousand USD | -7.64% |
| 2004 Q1 | 690.34 Thousand USD | -5.98% |
| 2004 Q4 | 565.83 Thousand USD | -3.8% |
| 2003 Q1 | 844.73 Thousand USD | -3.48% |
| 2003 FY | 734.25 Thousand USD | -16.11% |
| 2003 Q4 | 734.25 Thousand USD | -4.0% |
| 2003 Q3 | 764.83 Thousand USD | -3.86% |
| 2003 Q2 | 795.58 Thousand USD | -5.82% |
| 2002 Q4 | 875.22 Thousand USD | -3.95% |
| 2002 FY | 875.22 Thousand USD | -14.46% |
| 2002 Q1 | 980.22 Thousand USD | -4.2% |
| 2002 Q2 | 939.39 Thousand USD | -4.17% |
| 2002 Q3 | 911.17 Thousand USD | -3.0% |
| 2001 Q3 | 1.13 Million USD | -3.88% |
| 2001 FY | 1.02 Million USD | -46.27% |
| 2001 Q1 | 1.85 Million USD | -2.75% |
| 2001 Q4 | 1.02 Million USD | -9.93% |
| 2001 Q2 | 1.18 Million USD | -36.19% |
| 2000 FY | 1.9 Million USD | -7.01% |
| 2000 Q1 | 1.97 Million USD | -3.79% |
| 2000 Q2 | 1.89 Million USD | -3.72% |
| 2000 Q4 | 1.9 Million USD | -0.18% |
| 2000 Q3 | 1.9 Million USD | 0.56% |
| 1999 FY | 2.04 Million USD | -57.09% |
| 1999 Q1 | 4.22 Million USD | -11.95% |
| 1999 Q3 | 2.86 Million USD | -15.47% |
| 1999 Q4 | 2.04 Million USD | -28.47% |
| 1999 Q2 | 3.38 Million USD | -19.85% |
| 1998 Q4 | 4.8 Million USD | -7.69% |
| 1998 Q1 | 7.5 Million USD | 7400.0% |
| 1998 Q2 | 5.1 Million USD | -32.0% |
| 1998 FY | 4.77 Million USD | -36.08% |
| 1998 Q3 | 5.2 Million USD | 1.96% |
| 1997 Q3 | 7.5 Million USD | 1.35% |
| 1997 Q1 | 7.3 Million USD | 0.0% |
| 1997 Q4 | 100 Thousand USD | -98.67% |
| 1997 FY | 7.46 Million USD | 1.73% |
| 1997 Q2 | 7.4 Million USD | 1.37% |
| 1996 FY | 7.33 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | -335.653% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 23.217% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | -3.67% |
| Azitra, Inc. | 5.11 Million USD | -1550.557% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | -745.27% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -87495.315% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | -742.739% |
| CEL-SCI Corporation | 30.52 Million USD | -176.577% |
| iBio, Inc. | 28.73 Million USD | -193.847% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 16.418% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -1015.841% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | -28.754% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | -834.625% |
| NanoViricides, Inc. | 12.82 Million USD | -558.465% |
| Oragenics, Inc. | 4.96 Million USD | -1600.127% |
| BiomX Inc. | 58.15 Million USD | -45.185% |
| BiomX Inc. | 58.15 Million USD | -45.185% |
| Palatin Technologies, Inc. | 10.74 Million USD | -685.998% |
| Scorpius Holdings, Inc. | 51.03 Million USD | -65.435% |
| Theriva Biologics, Inc. | 60.21 Million USD | -40.23% |